AtriCure, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting third-quarter revenue of $154,450 thousand and net income of $4,064 thousand.
Key Highlights
- Quarterly revenue: $154,450 thousand for the three months ended September 30, 2026, compared with $134,269 thousand in the same period of 2025, according to the filing.
- Net income: $4,064 thousand for Q3 2026, versus a net loss of $267 thousand in Q3 2025, as reported in the condensed consolidated statements of operations.
- Nine-month revenue: $449,303 thousand for the nine months ended September 30, 2026, compared with $394,028 thousand for the same period in 2025.
- Nine-month net income: $13,127 thousand for the nine months ended September 30, 2026, compared with a net loss of $13,204 thousand in the prior-year period.
- Total assets: $717,536 thousand as of September 30, 2026, up from $654,179 thousand as of December 31, 2025.
- Shares outstanding: 50,913 thousand shares of common stock issued and outstanding as of September 30, 2026, per the condensed consolidated balance sheet.
- Accumulated deficit: $(400,076) thousand as of September 30, 2026, reduced from $(413,203) thousand as of December 31, 2025.
AtriCure Reports Quarterly and Year-to-Date Financial Results for the Period Ended September 30, 2026
AtriCure, Inc. (NASDAQ:ATRC), a Delaware corporation headquartered at 7555 Innovation Way, Mason, OH 45040, develops and sells surgical ablation and left atrial appendage management products. For the three months ended September 30, 2026, the company reported revenue of $154,450 thousand and gross profit of $119,350 thousand, compared with revenue of $134,269 thousand and gross profit of $101,332 thousand in the third quarter of 2025, according to the filing. Income from operations for Q3 2026 was $4,353 thousand, versus $208 thousand in the prior-year quarter.
For the nine months ended September 30, 2026, the filing disclosed revenue of $449,303 thousand and income from operations of $14,544 thousand, compared with revenue of $394,028 thousand and a loss from operations of $(11,938) thousand in the nine months ended September 30, 2025. Research and development expenses for the nine-month period rose to $82,753 thousand from $74,704 thousand in the comparable prior-year period. Selling, general and administrative expenses were $249,993 thousand for the nine months ended September 30, 2026, versus $232,676 thousand in the same period of 2025.
As of September 30, 2026, the company reported total assets of $717,536 thousand, including cash and cash equivalents of $187,031 thousand and goodwill of $234,781 thousand. Total stockholders' equity stood at $533,224 thousand, with additional paid-in capital of $933,234 thousand and an accumulated deficit of $(400,076) thousand. The filing noted share-based compensation expense of $36,064 thousand for the nine months ended September 30, 2026. Long-term debt was $61,000 thousand as of September 30, 2026, per the condensed consolidated balance sheet.
What Was Disclosed
AtriCure's Form 10-Q for the quarter ended September 30, 2026 disclosed quarterly revenue of $154,450 thousand, net income of $4,064 thousand, total assets of $717,536 thousand, and 50,913 thousand shares issued and outstanding as of the balance sheet date, as reported in the condensed consolidated financial statements.



Please wait processing your request...